You have 9 free searches left this month | for more free features.

adenocarcinoma of the gastroesophageal junction

Showing 1 - 25 of 3,746

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

Not yet recruiting
  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jul 17, 2023

Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)

Recruiting
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, China
    Peking Union Medical College Hospital
Jun 15, 2023

Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)

Recruiting
  • Gastric Cancer
  • +10 more
  • Kyiv, Ukraine
    National Cancer Institute
Aug 31, 2023

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

Recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • PD-1 inhibitor
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Aug 9, 2023

Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction Trial in Guangzhou (Docetaxel for injection (Albumin-bound),

Recruiting
  • Gastric Adenocarcinoma
  • Adenocarcinoma of Gastroesophageal Junction
  • Docetaxel for injection (Albumin-bound)
  • Taxotere
  • Guangzhou, China
    Ethics Committee of Sun-Yat-Sen University Cancer Center
Jan 27, 2023

Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with

Enrolling by invitation
  • Gastric / Gastroesophageal Junction Adenocarcinoma
  • envafolimab and lenvatinib combined with paclitaxel-albumin
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Sep 3, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (XELOX combined with Fruquintinib and Sintilimab)

Not yet recruiting
  • Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • XELOX combined with Fruquintinib and Sintilimab
  • (no location specified)
Oct 17, 2023

Gastric Cancer Trial (S-1, Oxaliplatin, Cadonilimab)

Not yet recruiting
  • Gastric Cancer
  • S-1, Oxaliplatin, Cadonilimab
  • (no location specified)
Jul 10, 2023

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

Active, not recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Jul 4, 2023

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric

Available
  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
  • +3 more
  • Morristown, New Jersey
    AMG Hematology/Oncology
Sep 15, 2023

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial (Ramucirumab, Paclitaxel)

No longer available
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jan 17, 2023

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, Beijing, China
  • +10 more
Nov 23, 2023

Esophageal Cancer Trial (Hypofractionated radiotherapy)

Not yet recruiting
  • Esophageal Cancer
  • Hypofractionated radiotherapy
  • (no location specified)
Jan 18, 2023

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial

Not yet recruiting
  • Advanced Esophageal Adenocarcinoma
  • +14 more
  • (no location specified)
Jan 3, 2023

Esophageal Adenocarcinoma Trial in Clermont-Ferrand (Adipose tissue biopsies)

Not yet recruiting
  • Esophageal Adenocarcinoma
  • Adipose tissue biopsies
  • Clermont-Ferrand, France
    CHU de Clermont-Ferrand
Jul 19, 2023

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical

Not yet recruiting
  • Clinical Stage I Esophageal Adenocarcinoma AJCC v8
  • +5 more
  • Biospecimen Collection
  • +9 more
  • Scottsdale, Arizona
  • +2 more
Oct 11, 2023

Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)

Recruiting
  • Advanced Gastric Adenocarcinoma
  • Henan, China
    Henan Tumor Hospital
Oct 13, 2022

Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III

Recruiting
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • +10 more
  • Biopsy
  • +8 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jan 20, 2023

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811;SHR-1701;capecitabine;oxaliplatin)

Not yet recruiting
  • HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jan 3, 2023

Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)

Not yet recruiting
  • Gastric Cancer
  • +3 more
  • LB1908
  • (no location specified)
Sep 9, 2022

Gastric Cancer, GastroEsophageal Cancer, Fruquintinib Trial in Nanning (Fruquintinib + SOX)

Recruiting
  • Gastric Cancer
  • +3 more
  • Fruquintinib + SOX
  • Nanning, China
    Guangxi Medical University Cancer Hospital
Dec 2, 2022

Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8,

Recruiting
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • +23 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 5, 2022